sacituzumab govitecan + anastrozole + exemestane

This combination therapy consists of the trophoblast cell-surface antigen 2 (Trop-2)-directed antibody-drug conjugate (ADC) sacituzumab govitecan and the aromatase inhibitors anastrozole or exemestane. It is being evaluated by Hunan Cancer Hospital in the Phase Ib/II SoGreat trial for patients with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer who have progressed on CDK4/6 inhibitors. Sacituzumab govitecan delivers the topoisomerase I inhibitor payload SN-38 directly to Trop-2-expressing cancer cells, while anastrozole and exemestane inhibit the enzyme aromatase, thereby reducing systemic estrogen levels and slowing the growth of hormone-sensitive tumors. The combination aims to overcome resistance to endocrine therapy by simultaneously targeting Trop-2 and the estrogen signaling pathway.

Other names

Sacituzumab Govitecan + Endocrine TherapySacituzumab Govitecan + Aromatase Inhibitors